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Immunosuppression associated with solid organ
transplantation significantly increases the rate of
nonmelanoma skin cancer (NMSC) development, in
particular squamous cell carcinomas (SCCs). In certain
cases, the rate at which these malignancies develop
can be too rapid for traditional surgical or field
treatments. In these cases, chemopreventative treat-
ments should be considered to decrease the rate of
NMSC development so that the remaining can be
managed by more traditional treatments. Herein, we
show that capecitabine can be used as a viable
chemopreventative option for these difficult cases.
CASE
Wepresent thecaseof a 68-year-oldwhitemanwho
had bilateral lung transplantation for smoking-related
chronic obstructive pulmonary disease on October 4,
2006 with excellent allograft function postoperatively.
The patient’s immunosuppressive medications were
limited to prednisone 5 mg daily and sirolimus 1 mg
daily.Before transplantation, thepatienthadnohistory
of nonmelanoma skin cancers. Approximately 1 year
after transplantation, he had his first skin cancer, an
SCC. He continued to have numerous SCCs, especially
on his scalp and hands, requiring multiple surgical
resections and reconstructions. By the timeof his death
in 2013 he had had 98 SCCs.
Because of rapid increase in number and aggres-
sive growth of his SCCs during his posttransplanta-
tion course, he started taking acitretin in June 2008,
beginning at 10 mg and titrated up to 25 mg. This
resulted in a modest but noticeable decrease in the
rate of NMSC development. Despite being on aci-
tretin, in 2009 he had a poorly differentiated SCC on
his right dorsal hand. The SCC showed in-transit
metastasis on punch biopsy of the ipsilateral forearmthe Division of Dermatology, University of California, Los
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Acitretin was discontinued, and he was treated with
chemotherapy consisting of 6 cycles of cisplatin and
5-fluouracil. He had an excellent response to therapy
with subsequent negative positron emission tomog-
raphy/computed tomography surveillance.
In 2010, he continued to have SCCs on his head
and neck. The patient started a skin cancer suppres-
sion regimen of capecitabine 1000 mg twice a day, 7
days on, 7 days off, for a total of 6 months. He
tolerated the therapy well with minimal side effects
and had a decreased incidence of cutaneous SCCs. In
2011, 6 months after completion of his course of
capecitabine, he again had subsequent multiple
SCCs; thus, he was given another regimen of
capecitabine, increased to 1500 mg twice a day, 7
days on, 7 days off, for a total of 6 months but was
ultimately stopped because of intolerance of side
effects.
Because of capecitabine therapy, SCCs were
developing at rate of approximately 18 per year.
After initiating therapy in March of 2010, the rate
decreased to 12 SCCs per year, a 33% reduction. After
stopping this first course, the patient again began to
have new lesions as noted by the small peak in 2011
(Fig 1). After this rebound, a second higher course of
capecitabine led to a durable response to decrease
his rate of SCC formation (Fig 1). This decrease lasted
until in 2012, when he had a recurrence of the right
dorsal hand metastatic SCC and was restarted onJAAD Case Reports 2015;1:S16-8.
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Fig 1. SCCs diagnosed per year for the patient presented. The 2 arrows indicate the initiation of
2 separate courses of capecitabine treatment.
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myelogenous leukemia.DISCUSSION
Compared with the general population, solid
organ transplant recipients (SOTRs) have a signifi-
cantly higher incidence of nonmelanoma skin
cancers.1 This is because of immunosuppressive
medication, with an increased degree of immuno-
suppression corresponding to an increased inci-
dence of NMSC. Skin cancers in SOTRs also tend to
behave more aggressively than in the general pop-
ulation and have a greater metastatic potential.2
Therefore, skin cancer screening and prevention
should be an integral part of any posttransplant
regimen.
Although surgical and physical interventions like
Mohs micrographic surgery and liquid nitrogen are
frequently used to manage cancerous and precan-
cerous lesions in SOTR, these lesions become a
burden, at which point adjuvant therapy should be
considered. Several adjuvant therapies exist to
reduce the number of NMSCs including topical 5-
fluorouracil (5-FU), topical imiquimod, topical and
systemic retinoids, and photodynamic therapy.
Acitretin is a systemic retinoid used as adjuvant
therapy in SOTRs for NMSC reduction and is often
considered in patients with significant SCC burden,
typically between 5 and 10 SCCs a year. Multiple
studies have found that acitretin leads to a statistically
significant reduction in SCCs in SOTRs with follow-
up ranging from 6 months to 5 years.3 A significant
number of patients are unable to tolerate the side
effects including severe xerosis, chelitis, and dry
eyes. Additionally, patients must be maintained on
systemic retinoids to avoid a rebound effect that
occurs if the medication is stopped, which can leadto the rapid development of numerous and aggres-
sive SCCs.
Capecitabine is a prodrug of 59-deoxy-5-
fluorouridine that is converted enzymatically to its
active metabolite 5-FU. It was initially approved by
the US Food and Drug Administration in 1998 for
breast cancer and subsequently in 2001 and 2005 for
metastatic and primary colon cancer, respectively. It
was observed that in some breast cancer patients
being treated with capecitabine, actinic keratoses
became inflamed and some subsequently resolved.4
This observation is similar to the effects of topically
applied 5-FU.
Oral low-dose capecitabine has since been used
in certain cases for chemoprevention of NMSC in
SOTR.5 It is typically administered at 0.5 to 1.5 g/m2
daily for days 1 to 14 of a 21-day treatment cycle.
Treatment cycles are repeated until disease progres-
sion or the development of intolerable toxicity.
Studies have shown this regimen to induce a statis-
tically significant reduction of both SCCs and actinic
keratoses.
Although low-dose capecitabine is tolerated well
by most patients, treatment-limiting side effects may
be observed in up to 30% of patients.6 The most
commonly reported side effects include fatigue,
diarrhea, hand-foot syndrome, neutropenic fever,
and stomatitis.
Prior to initiating treatment, patients should be
screened for dihydropyrimidine dehydrogenase
deficiency.6 If present, this may lead to severe
capecitabine toxicity. Additionally, renal function
should be assessed before treatment, as impaired
function may contribute to the development of
severe side effects.
In our case, capecitabine was used as adjuvant
preventive therapy in a SOTR with a resultant
significant decrease of his SCC disease burden. The
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metastatic disease was successfully maintained for 2
years with 2 separate regimens of capecitabine.
Further studies are needed to help define the role
that capecitabine plays in the prevention of NMSC in
SOTRs. Future research may help improve the
tolerability of the treatment and limit side effects.
We suggest that for certain SOTR patients with
significant NMSC burden that capecitabine offers a
viable adjuvant therapy to help control disease.
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